Yazar "Elitok, Ali" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Association Between Genetic Variants of DNA Repair Genes and Coronary Artery Disease
    (Mary Ann Liebert, Inc, 2013) Gökkuşu, Cahide; Çakmakoğlu, Bedia; Daşdemir, Selçuk; Tülübaş, Feti; Elitok, Ali; Tamer, Sule; Umman, Berrin
    Polymorphisms in DNA repair genes may be associated with differences in the repair efficiency of DNA damage and may influence an individual's risk of atherosclerosis. Genetic research on coronary artery disease (CAD) has traditionally focused on investigation aimed at identifying disease-susceptibility genes. The aim of this study was to investigate the relationship between AP-endonuclease-1 (Asp148Glu), XRCC1 (Arg399Gln), XRCC3 (Thr241Met), XPD (Lys751Gln), XPG (Asp1104His), and hOGG1 (Ser326Cys), gene polymorphisms and the risk of developing CAD in a Turkish population. The study population consisted of 197 patients with acute coronary syndrome (ACS) with chronic CAD and 135 healthy subjects' age and sex matched. Gene polymorphisms were determined by the polymerase chain reaction-restriction fragment length polymorphism method. We demonstrated for the first time, a positive association of XRCC3 and hOGG1 DNA repair gene variants with CAD risk. XRCC3 Thr/Thr genotype and Thr allele frequencies were significantly increased in ACS and chronic CAD patients compared with the control group (p < 0.05). It was also observed that there is a protective role of XRCC3 Met alleles against both ACS and chronic CAD (p < 0.05). hOGG1 Cys alleles were found significantly higher in ACS patients than in the control group and carriers of the Cys allele had a 1.7-fold increased risk for ACS. In addition, we confirmed the association of XRCC3 Thr241Met and hOGG1 Ser326Cys gene variants with CAD by haplotype analysis. We found that CAD risk is associated with XRCC3 Thr: hOGG1 Cys haplotype, whereas XRCC3 Met: hOGG1 Ser haplotype was found to be protective against the disease. The preliminary results suggested that XRCC3 and hOGG1 genetic variants may be risk factors by affecting the enzyme's function that may lead to development of CAD.
  • Küçük Resim
    Öğe
    Does aspirin use prevent acute coronary syndrome in patients with pneumonia: multicenter prospective randomized trial
    (Lippincott Williams & Wilkins, 2013) Öz, Fahrettin; Gül, Sule; Kaya, Mehmet G.; Yazıcı, Mehmet; Bulut, İsmet; Elitok, Ali; Oflaz, Hüseyin; Akkoyun, Cayan D.
    Objectives The aim of this study was to test the hypothesis that aspirin would reduce the risk for acute coronary syndromes (ACSs) in patients with pneumonia. Backgrounds Pooled data suggest that pneumonia may trigger an ACS as a result of inflammatory reactions and the prothrombotic changes in patients with pneumonia. Hypothetically considering its antiaggregating and anti-inflammatory effects, aspirin might also be beneficial for the primary prevention of ACS in patients with pneumonia. Methods One hundred and eighty-five patients with pneumonia who had more than one risk factor for cardiovascular disease were randomized to an aspirin group (n = 91) or a control group (n = 94). The patients in the aspirin group received 300 mg of aspirin daily for 1 month. ECGs were recorded on admission and 48 h and 30 days after admission to assess silent ischemia. The level of high-sensitivity cardiac troponin T was measured on admission and 48 h after admission. The primary endpoint was the development of ACS within 1 month. The secondary endpoints included cardiovascular death and death from any cause within 1 month. Results The chi(2)-test showed that the rates of ACS at 1 month were 1.1% (n = 1) in the aspirin group and 10.6% (n = 10) in the control group (relative risk, 0.103; 95% confidence interval 0.005-0.746; P = 0.015). Aspirin therapy was associated with a 9% absolute reduction in the risk for ACS. There was no significant decrease in the risk of death from any cause (P = 0.151), but the aspirin group had a decreased risk of cardiovascular death (risk reduction: 0.04, P = 0.044). Conclusion This randomized open-label study shows that acetyl salicylic acid is beneficial in the reduction of ACS and cardiovascular mortality among patients with pneumonia. Coron Artery Dis 24:231-237 (c) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. Coronary Artery Disease 2013, 24:231-237